122 Regimented Phosphodiesterase Type 5 Inhibitor Use Reduces Emergency Department Visits for Recurrent Ischemic Priapism

Abstract

Priapism is an erection disorder defined by an undesirable and often painful penile erection that persists in the absence of sexual desire or arousal. Recurrent ischemic priapism (RIP) manifests as multiple repetitive episodes over time and can have potentially irreversible pathologic consequences. The ideal strategy for managing RIP is preventative therapy. Current treatment options are often ineffective, have significant adverse effects, and have limited evidence. A recently recognized proposal has been the use of regimented phosphodiesterase type 5 inhibitor (regPDE5i) therapy intended to modulate the deranged regulatory mechanisms of penile erection in RIP. Previous reports on this strategy, mostly in small clinical trials and case series, have documented encouraging outcomes. However, its effectiveness as a treatment in use more extensively in real-world clinical practice remains to be shown.